<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudomonas aeruginosa bacteremia and endocarditis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudomonas aeruginosa bacteremia and endocarditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudomonas aeruginosa bacteremia and endocarditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Souha S Kanj, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is among the top considerations in the differential diagnosis when treating patients who are suspected of having severe hospital-acquired infections.</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of <em>P. aeruginosa</em> bacteremia and endocarditis will be reviewed here. </p><p>The general principles of antimicrobial treatment of infections caused by <em>P. aeruginosa</em>, including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p>The clinical manifestations and management of other <em>P. aeruginosa</em> infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3148.html" rel="external">"Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pseudomonas aeruginosa'</a> and  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.) </p><p></p><p class="headingAnchor" id="H2"><span class="h1">BACTEREMIA</span></p><p class="headingAnchor" id="H3"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Bloodstream infection (BSI) with <em>P. aeruginosa</em> is most commonly hospital-acquired and is a problem worldwide [<a href="#rid1">1-6</a>]. In a prospective analysis from the SCOPE (Surveillance and Control of Pathogens of Epidemiologic Importance) database of 24,179 hospital-acquired bloodstream infections occurring in 49 hospitals in the United States between 1995 to 2002, <em>Pseudomonas</em> species accounted for 4 percent of cases and were the third leading cause of gram-negative infections [<a href="#rid5">5</a>]. In certain settings, such as intensive care units, the proportion of gram-negative bloodstream infections due to <em>P. aeruginosa</em> is even higher. As an example, in one review of liver transplant recipients, approximately 35 percent of bloodstream infections were with <em>P. aeruginosa</em>, which had an attributable mortality of 30 percent [<a href="#rid7">7</a>]. In a retrospective study, <em>Pseudomonas </em>spp was the second most common cause of gram-negative BSIs after <em>E. coli</em> (31 percent) in BSIs among patients with hematologic or solid organ malignancies [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Microbiology'</a> and  <a class="medical medical_review" href="/d/html/3806.html" rel="external">"Intravascular catheter-related infection: Epidemiology, pathogenesis, and microbiology"</a>.)</p><p>Risk factors for <em>P. aeruginosa</em> bacteremia include [<a href="#rid3">3,6,9-15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection)</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatobiliary tract disease</p><p class="bulletIndent1"><span class="glyph">●</span>Severe burns</p><p class="bulletIndent1"><span class="glyph">●</span>Indwelling central venous or urinary catheter</p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial use within the prior three months (eg, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, antipseudomonal carbapenem, fluoroquinolone, aminoglycoside, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> use) [<a href="#rid15">15,16</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Traumatic wounds that have been contaminated with fresh water</p><p class="bulletIndent1"><span class="glyph">●</span>Recent hospitalization </p><p></p><p><em>P. aeruginosa</em> bacteremia in immunocompetent patients is primarily associated with the use of indwelling urinary, central venous catheters, or traumatic or surgical wound infections [<a href="#rid17">17</a>]. A case-control study of Korean patients with <em>P. aeruginosa</em> bacteremia in the emergency department setting found that respiratory tract infection was an independent risk factor, whereas diabetes mellitus and urinary tract infection were negative clinical predictors [<a href="#rid18">18</a>].</p><p>Pancreatobiliary tract disease is an additional important risk factor for bacteremia, independent of underlying malignancy or immunosuppression [<a href="#rid19">19</a>]. Pancreatobiliary sources and complications from endoscopic retrograde cholangiopancreatography (ERCP) appear to be increasing in frequency as the cause of <em>P. aeruginosa</em> bacteremia in many regions. Clusters of <em>P. aeruginosa</em> bacteremias after ERCP have been traced to inadequate cleaning or disinfection of endoscopes [<a href="#rid20">20</a>].</p><p>Hospital-acquired <em>P. aeruginosa</em> bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues, or from infected intravascular catheters [<a href="#rid4">4,19,21</a>]. The source of the bacteremia is unknown in up to 40 percent of cases.</p><p class="headingAnchor" id="H4"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Although it is usually impossible to distinguish patients with <em>P. aeruginosa</em> bacteremia from patients with bacteremia due to other gram-negative rods based on clinical features alone, patients with <em>P. aeruginosa</em> infection are more likely to have a fatal outcome. (See <a class="local">'Prognosis'</a> below.)</p><p>Patients with gram-negative bacteremia due to <em>P aeruginosa</em> typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure (due to either pneumonia or acute respiratory distress syndrome [ARDS]) are other common complications, especially in immunocompromised or debilitated patients. Additional clinical manifestations will vary by the site of the primary infection. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/1597.html" rel="external">"Pathophysiology of sepsis"</a>.)</p><p>Rarely, patients with <em>P. aeruginosa</em> bacteremia develop ecthyma gangrenosum  (<a class="graphic graphic_picture graphicRef80582" href="/d/graphic/80582.html" rel="external">picture 1</a>), a skin lesion that results from perivascular bacterial invasion of the media and adventitia of arteries and veins with secondary ischemic necrosis. Although ecthyma gangrenosum is not pathognomonic of <em>P. aeruginosa</em> infection, the presence of these lesions should immediately raise the high probability that <em>P. aeruginosa</em> is the causative organism. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections", section on 'Ecthyma Gangrenosum'</a>.)</p><p>Other skin lesions that may occasionally accompany pseudomonal bacteremia include: diffuse maculopapular lesions, painful clusters of small vesicles or pustules, flat sharply-demarcated areas of cellulitis that may initially mimic erysipelas and become necrotic with time, and metastatic soft tissue abscesses that may appear on the extremities and fingertips [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H2709903784"><span class="h3">Empiric antibiotic therapy</span><span class="headingEndMark"> — </span>Prompt administration of effective antimicrobial therapy is a critical initial step in the management of <em>P. aeruginosa</em> bacteremia  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>) as delayed therapy correlates with increased mortality (see <a class="local">'Prognosis'</a> below). We favor the use of combination antimicrobial therapy for empiric therapy of known or suspected <em>P. aeruginosa</em> bacteremia prior to determination of drug susceptibility. In high-risk patients (such as those with neutropenia or severe burns and others with sepsis/shock), the rationale for the use of combination therapy in select situations is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.) </p><p>Selection of empiric agents should also be informed by the local <em>P. aeruginosa</em> susceptibility patterns. Discussion of empiric therapy for gram-negative rod bacteremia and when <em>P. aeruginosa</em> should be covered is also found elsewhere. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Empiric antimicrobial therapy'</a> and  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Indications and rationale for coverage of P. aeruginosa'</a>.) </p><p class="headingAnchor" id="H2108226022"><span class="h3">Directed antibiotic therapy and duration</span><span class="headingEndMark"> — </span>When the isolate and results of susceptibility testing are known, antimicrobial therapy should be adjusted accordingly. In general, there is no convincing clinical evidence that using two active antipseudomonal agents offers a mortality benefit over a single active agent. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Rationale'</a>.)</p><p>Thus, for most patients with <em>P. aeruginosa</em> bacteremia, we suggest directed therapy with a single intravenous antipseudomonal antibiotic to which the isolate is susceptible  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>); however, aminoglycosides should not be used as a single agent. </p><p>Treatment duration is largely dictated by the primary site of infection. </p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompetent patients, we administer antibiotic therapy for 7 to 10 days as long as source control has been achieved (eg, via removal of infected catheters or drainage of abscesses ); if patients responded promptly to these interventions and antimicrobial therapy; and there is no bony, endovascular, pulmonary, or central nervous system (CNS) involvement. If the isolate is susceptible to fluoroquinolones and there are no concerns about gastrointestinal tract absorption of oral medications, patients can be transitioned to oral <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> or <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> to complete their course of therapy. Longer courses of therapy may be warranted if source control is uncertain or if there are known seeded sites of infection that are not amenable to drainage. Duration of treatment for <em>P. aeruginosa</em> osteomyelitis, endocarditis, pneumonia, and CNS infection are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment", section on 'Clinical approach'</a> and <a class="local">'Treatment'</a> below and  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Duration'</a>.)</p><p></p><p class="bulletIndent1">Limited observational data support this relatively abbreviated course of antibiotics for uncomplicated <em>P. aeruginosa</em> bacteremia [<a href="#rid24">24,25</a>]. In a retrospective study of 249 patients with <em>P. aeruginosa</em> bacteremia, a shorter duration of antibiotics (7 to 11 days, median 9) was associated with a similar odds of death and recurrent infection as a longer duration (11 to 21 days, median 16) after adjustment for risk factors for severe disease [<a href="#rid24">24</a>]. Almost all patients had appropriate source control, and patients treated for more than 21 days, presumably because of complicated infections, were not included. The antibiotic courses included a step down to an oral fluoroquinolone in about a third of patients in both groups. Despite the limitations of this study, including unmeasured confounders, these data support a conclusion that an abbreviated course can be an appropriate strategy for select patients.</p><p></p><p class="bulletIndent1">However, the optimal duration of therapy remains uncertain when dealing with bacteremia due to MDR <em>P. aeruginosa</em>, as most studies have not critically examined outcomes by the duration of therapy. Moreover, studies focusing on novel antibiotics with activity against MDR gram-negative bacilli compared outcomes with existing standards of care or to the best available therapy. Total durations of treatment in such studies varied from 5 to 21 days depending on the specific clinical trial protocols, the sites of infection, and assessments of clinical response. Thus at present we can make no firm recommendations as to the optimal duration of therapy for patients with MDR <em>P. aeruginosa </em>bacteremia [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For neutropenic patients, we use a single active agent and continue it for at least 14 days and until the neutrophil count has recovered. Some experts continue to use two intravenous antipseudomonal antibiotics from different classes to which the isolate is susceptible for the first three to five days of treatment to ensure clinical improvement because of the high mortality risk, despite the absence of data to support the practice. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>See other topic reviews for duration of treatment for other types of infection (eg, pneumonia, soft tissue infection, biliary infection) that may be complicated by bacteremia. </p><p></p><p>Antipseudomonal agents and their dosing are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p class="headingAnchor" id="H3643595515"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>In addition to antimicrobial therapy, the primary site of infection should also be addressed. All infected catheters should be removed, and abscesses or obstructions should be drained or removed whenever possible.</p><p class="headingAnchor" id="H8"><span class="h2">Prognosis</span></p><p class="headingAnchor" id="H42033779"><span class="h3">Mortality</span><span class="headingEndMark"> — </span>Bacteremia due to <em>P. aeruginosa</em> is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli or gram-positive organisms [<a href="#rid27">27-30</a>]. </p><p>One study, which prospectively compared 314 patients with bacteremia due to <em>P. aeruginosa</em> or <em>S. aureus</em>, found that mortality was significantly higher with <em>P. aeruginosa</em> than with either methicillin-susceptible <em>S. aureus</em> (MSSA) or methicillin-resistant <em>S. aureus</em> (MRSA) (30.6 percent, 16.2 percent, and 13.5 percent, respectively) [<a href="#rid27">27</a>]. In a retrospective analysis of 136 patients with <em>P. aeruginosa</em> bacteremia, the 30-day mortality rate was 39 percent [<a href="#rid28">28</a>]. Similar mortality rates have been reported among children and adolescents with <em>P. aeruginosa</em> bacteremia in the setting of neutropenia [<a href="#rid29">29</a>].</p><p>The reported 30-day mortality attributable to carbapenem-resistant <em>P. aeruginosa</em> bacteremia is also high, ranging between 8 and 18.4 percent [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H42033785"><span class="h3">Risk factors for poor prognosis</span><span class="headingEndMark"> — </span>Mortality is especially high in neutropenic patients and in patients who present with or develop septic shock. </p><p>In a study of 133 episodes of <em>P. aeruginosa</em> bacteremia, a stepwise logistic regression analysis identified four variables as independently influencing outcome [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Development of septic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Granulocyte count &lt;500/mm3</p><p class="bulletIndent1"><span class="glyph">●</span>Inappropriate initial antibiotic therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Development of septic metastasis</p><p></p><p>Other studies have shown that the prognosis of <em>P. aeruginosa</em> bacteremia is closely related to the underlying condition of the host and the primary site of infection. In a study of 100 episodes of <em>P. aeruginosa</em> bacteremia, survival directly correlated with underlying disease [<a href="#rid32">32</a>]. Twenty-six of 47 patients (55 percent) with nonfatal underlying conditions survived, compared with 2 of 13 (15 percent) and 16 of 64 (25 percent) with rapidly fatal and ultimately fatal underlying conditions, respectively. Mortality is also usually higher when the bacteremia accompanies a pulmonary infection [<a href="#rid33">33</a>]. In one study, patients with underlying malignancy (hematologic or solid organ) were shown to have a 30-day mortality of 22 percent following <em>Pseudomonas</em>-associated BSI [<a href="#rid8">8</a>].</p><p>Drug resistance may also negatively impact prognosis. Two studies found that strains of <em>P. aeruginosa</em> that produce metallo-beta-lactamases or specific (PER-1) extended spectrum beta-lactamases cause unusually high mortality rates when present in the bloodstream [<a href="#rid34">34,35</a>]. In a prospective multicenter study of 632 cases of <em>P. aeruginosa</em> bacteremia, carbapenem resistance (n = 145) was not associated with higher mortality overall (35 versus 27 percent with susceptible strains); however, in a subgroup analysis, higher 30-day mortality rates were noted among patients with few comorbidities when carbapenem resistance was present (adjusted odds ratio [OR] 6 to 10) [<a href="#rid36">36</a>]. Variables that have been associated with mortality in patients with BSI due to MDR <em>P. aeruginosa</em> include presentation with septic shock and inadequate initial antimicrobial therapy [<a href="#rid37">37</a>]. </p><p>Other factors that have been associated with poor prognosis include the presence of polymicrobial (versus monomicrobial bacteremia) and advanced age [<a href="#rid28">28,38,39</a>]. In a study of patients with hematologic malignancies who had <em>Pseudomonas</em> infections, hypophosphatemia, hypoproteinemia, and high serum lactate were associated with an increased risk of septic shock on multivariate analysis [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H42033811"><span class="h3">Effect of antimicrobial therapy on prognosis</span><span class="headingEndMark"> — </span>The choice and timing of antibiotic therapy is particularly crucial. As an example, in one study of 410 episodes of <em>P. aeruginosa</em> bacteremia, cure was substantially higher in patients receiving appropriate antibiotics than in those who did not (67 versus 14 percent), and a one- to two-day delay in administering appropriate antibiotics reduced the cure rate from 74 to 46 percent [<a href="#rid41">41</a>]. In one prospective ICU study, inadequate antimicrobial therapy was statistically associated with a higher mortality rate (62 versus 28 percent, RR 2.18, 95 percent CI 5.09-9.24, p&lt;0.001) [<a href="#rid42">42</a>]. Approximately 10 percent of patients in this study had <em>P. aeruginosa</em> bacteremia.</p><p>The prognosis of <em>P. aeruginosa</em> bacteremia in neutropenic patients with hematologic malignancies has improved over time [<a href="#rid43">43</a>]. One retrospective study showed an improved prognosis of <em>P. aeruginosa</em> bacteremia in the years 1992 to 1996 compared with 1976 to 1982 [<a href="#rid44">44</a>]. This improvement was due mainly to changes in the management of the infection:</p><p class="bulletIndent1"><span class="glyph">●</span>More frequent use of new anti-pseudomonal beta-lactams and <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> instead of aminoglycosides as monotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prompt removal of catheters.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">ENDOCARDITIS</span></p><p class="headingAnchor" id="H296144973"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Infective endocarditis (IE) due to <em>P. aeruginosa</em> is uncommon, but when it occurs, it is strongly associated with injection drug use (IDU) and/or prosthetic heart valves [<a href="#rid45">45</a>] and pacemakers. More than 90 percent of cases of IE due to <em>P. aeruginosa</em> have been reported in people who inject drugs (PWID), and most patients had no previous structural heart disease. <em>P. aeruginosa</em> IE tends to occur in specific geographic locations; epidemics of this infection have been described in PWID, mainly users of <a class="drug drug_general" data-topicid="9753" href="/d/drug information/9753.html" rel="external">pentazocine</a> and tripelennamine, presumably associated with mixing of drugs in contaminated water [<a href="#rid46">46,47</a>]. </p><p><em>P. aeruginosa</em> is also an occasional cause of hospital-acquired endocarditis, accounting for 10 percent of cases in one small ICU series [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>In general, the clinical manifestations of IE are similar whether due to <em>P. aeruginosa</em> or other organisms. However, given the close association with IDU, the most frequently involved valve is the tricuspid. Additionally, multiple valve involvement can occur. In a study of 34 cases from one center, 13 had isolated involvement of the tricuspid valve and an additional case had tricuspid and pulmonic valve infection [<a href="#rid49">49</a>]. </p><p>Since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Such patients often have multiple discrete lung lesions that may progress to cavitation. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis"</a>.)</p><p>Patients with tricuspid valve infection typically have a less fulminant course and better prognosis than patients with left-sided valvular involvement. In one study, 20 of 25 patients with right-sided infection recovered with medical or combined medical/surgical therapy compared with only three of nine patients with left-sided infection [<a href="#rid50">50</a>].</p><p>The clinical manifestations of endocarditis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>In the setting of <em>P. aeruginosa</em> bacteremia, the diagnosis of endocarditis can be made with echocardiography and application of the Duke Criteria for endocarditis. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p>The vast majority of patients with <em>P. aeruginosa</em> bacteremia do not have IE, and even those patients who have underlying risk factors for IE, such as patients with prosthetic heart valves, can have <em>P. aeruginosa</em> bacteremia in association with a urinary tract or wound infection. Thus, it would be impractical and of low yield to perform echocardiography in all patients with <em>P. aeruginosa</em> bacteremia. We evaluate for IE among patients with <em>P. aeruginosa</em> bacteremia in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Failure to clear bloodstream infection on appropriate therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of other stigmata of IE, including new regurgitant murmurs or evidence of embolic disease to the periphery, lungs, or central nervous system</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of underlying conditions increasing the risk of IE, including injection drug use, prosthetic valve, cardiac devices, and a previous history of endocarditis [<a href="#rid51">51</a>]. In an observational study of bacteremia in patients with cardiac devices, pseudomonal bacteremia was highly associated with cardiac device-related infection (odds ratio 50.28, 95% CI 4.16-606.93) compared with bacteremia from other gram-negative organisms [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment of <em>P. aeruginosa</em> IE usually necessitates the combination of antibiotics and surgery to achieve cure [<a href="#rid2">2</a>]. This is based on the fact that beta-lactam antibiotics have a slow onset of bactericidal activity against the organism, lack a postantibiotic effect, and can rapidly induce the development of resistance.</p><p>For antimicrobial therapy of <em>P. aeruginosa</em> IE, we suggest combination therapy with two intravenous antipseudomonal antibiotics from different classes to which the isolate is susceptible  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>); one antibiotic should be an aminoglycoside unless the use is precluded by nephrotoxicity. The duration of therapy should be for at least six weeks. There are no published data comparing combination to monotherapy for <em>P. aeruginosa</em> IE, as it is a relatively uncommon infection; the vast majority of the published literature describes treatment with a combination antimicrobial regimen [<a href="#rid47">47,53</a>]. Specific antipseudomonal agents and their doses are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'</a>.)</p><p>We routinely obtain early surgical consultation in all cases of <em>P. aeruginosa</em> endocarditis because of the association of improved prognosis with early valve replacement, particularly in the setting of left-sided disease (see <a class="local">'Prognosis'</a> below). When splenic abscesses complicate <em>P. aeruginosa</em> IE, splenectomy should be performed prior to valve replacement. </p><p>Additional surgical issues for native and prosthetic valve endocarditis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2148.html" rel="external">"Surgery for left-sided native valve infective endocarditis"</a> and  <a class="medical medical_review" href="/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>.)</p><p>Phage therapy has been evaluated for <em>P. aeruginosa</em> endovascular infections in case reports and animal studies [<a href="#rid54">54,55</a>]. This strategy remains investigational; the frequency and significance of acquired resistance to phage treatment are uncertain issues. </p><p class="headingAnchor" id="H13"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> endocarditis is associated with a poor outcome. In one study in patients with <em>S. aureus</em> and <em>P. aeruginosa</em> bacteremia, endocarditis was found to be an independent determinant of hospital mortality (OR 4.62; 95 percent CI 2.45-8.73) [<a href="#rid27">27</a>].In a review of 27 cases of<em> P. aeruginosa </em>IE in patients without injection drug use, mortality rates were 29 and 40 percent for community-acquired and hospital-acquired cases, respectively [<a href="#rid56">56</a>]. Age &gt;60 years and a prosthetic device source were associated with even higher mortality rates. </p><p>In patients with left-sided IE due to <em>P. aeruginosa</em>, the prognosis for medical therapy is worse than for combined medical and surgical therapy in endocarditis due to most other organisms [<a href="#rid46">46,47</a>]. Early valve replacement has been shown to improve prognosis and is indicated in cases refractory to medical treatment and in complicated cases with hemodynamic instability. (See  <a class="medical medical_review" href="/d/html/2148.html" rel="external">"Surgery for left-sided native valve infective endocarditis"</a>.) </p><p class="headingAnchor" id="H1672613594"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112042.html" rel="external">"Society guideline links: Treatment and prevention of infective endocarditis"</a>.)</p><p class="headingAnchor" id="H296145128"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. Consideration of this organism is important because it causes severe hospital-acquired infections, especially in immunocompromised hosts, is often antibiotic resistant, complicating the choice of therapy, and is associated with a high mortality rate. (See <a class="local">'Introduction'</a> above.)</p><p class="headingAnchor" id="H296145101"><span class="h2">Bacteremia</span></p><p class="bulletIndent1"><span class="glyph">●</span>Bloodstream infection with <em>P. aeruginosa</em> is most commonly hospital-acquired. Risk factors for <em>P. aeruginosa</em> bacteremia include neutropenia or other immunodeficiency (eg, hematologic malignancy, solid organ or bone marrow transplantation, or HIV infection), advanced age, pancreatobiliary tract disease, severe burns, an indwelling central venous or urinary catheter, antimicrobial therapy within the last 30 days, and traumatic wounds that have been contaminated with fresh water. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospital-acquired <em>P. aeruginosa</em> bacteremia may result from primary infection in the lungs, biliary and gastrointestinal tract, urinary tract, skin and soft tissues or from infected intravascular catheters. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremic patients typically present with fever, tachycardia, and tachypnea. Disorientation, hypotension, and respiratory failure due to either pneumonia or acute respiratory distress syndrome are other common complications, especially in immunocompromised or debilitated patients. Although it is usually impossible to distinguish patients with <em>P. aeruginosa</em> bacteremia from patients with bacteremia due to other gram-negative rods on clinical grounds alone, patients with <em>P. aeruginosa</em> infection are more likely to have a fatal outcome and to develop ecthyma gangrenosum. The lesions of ecthyma gangrenosum  (<a class="graphic graphic_picture graphicRef80582" href="/d/graphic/80582.html" rel="external">picture 1</a>) involve the skin or mucous membranes, beginning as a small area of edema and quickly evolving into painless nodular lesions with central hemorrhage, ulceration, and necrosis. (See <a class="local">'Clinical features'</a> above and  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections", section on 'Ecthyma Gangrenosum'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prompt empiric therapy with an active antimicrobial agent  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>) is critical in the management of known or suspected <em>P. aeruginosa</em> bacteremia, as delayed therapy correlates with increased mortality. In certain high risk patients (eg, patients with neutropenia or severe burns) and those with severe infections (eg, patients with sepsis/shock), we favor the use of combination antimicrobial therapy for empiric therapy. Otherwise, a single antipseudomonal agent is likely appropriate. In addition, infected catheters should be removed, and abscesses or obstructions should be drained or removed, whenever possible. The rationale for combination therapy in select settings is discussed elsewhere. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Empiric antimicrobial therapy'</a> and  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the isolate and results of susceptibility testing are known, antimicrobial therapy should be adjusted accordingly. In general, there is no clinical evidence that using two active antipseudomonal agents offers a mortality benefit over a single active agent. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1">Thus, for most patients with <em>P. aeruginosa</em> bacteremia, we suggest treatment with a single intravenous antipseudomonal antibiotic to which the isolate is susceptible instead of a combination antimicrobial regimen  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Aminoglycosides should not be used as a single agent. However, because of the high associated mortality rate of <em>P. aeruginosa</em> bacteremia in the setting of neutropenia, it is reasonable to continue a second active antipseudomonal agent for the first three to five days of treatment of neutropenic patients pending clinical improvement.</p><p></p><p class="bulletIndent1">For immunocompetent patients with uncomplicated bacteremia and appropriate source control, we suggest a 7- to 10-day course of antibiotics (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Longer courses are warranted when source control is not adequate; when there is bony, endovascular, pulmonary, or central nervous system involvement; and in immunocompromised patients, such as those with neutropenia. (See <a class="local">'Directed antibiotic therapy and duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia due to <em>P. aeruginosa</em> is associated with a high mortality rate compared with bacteremia due to other gram-negative bacilli as well as gram-positive organisms. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H296145136"><span class="h2">Endocarditis</span></p><p class="bulletIndent1"><span class="glyph">●</span>Infective endocarditis (IE) due to <em>P. aeruginosa</em> is uncommon, but when it occurs, it is strongly associated with injection drug use (IDU) and/or prosthetic heart valves and pacemakers. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the close association with IDU, the most frequently involved valve is the tricuspid valve. Additionally, multiple valve involvement can occur. Since tricuspid infection is common, many patients present with pulmonary manifestations, including cough, chest pain, and hemoptysis. Patients with left-sided valvular infections often develop fulminant or rapidly progressive symptoms that are due to either congestive heart failure or embolism of large or medium-sized arteries. Ring and annular abscesses are also frequent complications. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of <em>P. aeruginosa</em> bacteremia, the diagnosis of endocarditis can be made with echocardiography and application of the Duke Criteria for endocarditis. In the absence of specific risk factors and signs of endocarditis, patients with <em>P. aeruginosa</em> bacteremia do not require work-up for endocarditis. (See  <a class="medical medical_review" href="/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <em>P. aeruginosa</em> infective endocarditis, we suggest combination antimicrobial therapy for the duration of the treatment course (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This regimen should include two antipseudomonal antibiotics from different classes to which the isolate is susceptible  (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 1</a>). (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest early<strong> </strong>surgical consultation in all cases of <em>P. aeruginosa</em> endocarditis because of the association of improved prognosis with early valve replacement or repair (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Particularly in patients with left-sided disease, the prognosis for medical therapy is worse than for combined medical and surgical therapy. (See <a class="local">'Treatment'</a> above and <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Al-Hasan MN, Wilson JW, Lahr BD, et al. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med 2008; 121:702.</a></li><li><a class="nounderline abstract_t">National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control 1996; 24:380.</a></li><li><a class="nounderline abstract_t">Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156:2121.</a></li><li><a class="nounderline abstract_t">Sifuentes-Osornio J, Gonzalez R, Ponce-de-Leon A, Guerrero ML. Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center. Rev Invest Clin 1998; 50:383.</a></li><li><a class="nounderline abstract_t">Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.</a></li><li><a class="nounderline abstract_t">Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.</a></li><li><a class="nounderline abstract_t">Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist 2018; 11:2345.</a></li><li><a class="nounderline abstract_t">Amanati A, Sajedianfard S, Khajeh S, et al. Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance. BMC Infect Dis 2021; 21:636.</a></li><li><a class="nounderline abstract_t">Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 2009; 48:580.</a></li><li><a class="nounderline abstract_t">Mendelson MH, Gurtman A, Szabo S, et al. Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18:886.</a></li><li><a class="nounderline abstract_t">Shepp DH, Tang IT, Ramundo MB, Kaplan MK. Serious Pseudomonas aeruginosa infection in AIDS. J Acquir Immune Defic Syndr 1994; 7:823.</a></li><li><a class="nounderline abstract_t">Leigh L, Stoll BJ, Rahman M, McGowan J Jr. Pseudomonas aeruginosa infection in very low birth weight infants: a case-control study. Pediatr Infect Dis J 1995; 14:367.</a></li><li><a class="nounderline abstract_t">Dropulic LK, Leslie JM, Eldred LJ, et al. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 1995; 171:930.</a></li><li><a class="nounderline abstract_t">Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79.</a></li><li><a class="nounderline abstract_t">Vuotto F, Berthon C, Lemaitre N, et al. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Am J Infect Control 2013; 41:527.</a></li><li><a class="nounderline abstract_t">Gudiol C, Albasanz-Puig A, Laporte-Amargós J, et al. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Healey LA, Backes MB. Nitritoid reactions and angiotensin-converting-enzyme inhibitors. N Engl J Med 1989; 321:763.</a></li><li><a class="nounderline abstract_t">Choi Y, Paik JH, Kim JH, et al. Clinical Predictors of Pseudomonas aeruginosa Bacteremia in Emergency Department. Emerg Med Int 2018; 2018:7581036.</a></li><li><a class="nounderline abstract_t">Chen SC, Lawrence RH, Byth K, Sorrell TC. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor? Med J Aust 1993; 159:592.</a></li><li><a class="nounderline abstract_t">Classen DC, Jacobson JA, Burke JP, et al. Serious Pseudomonas infections associated with endoscopic retrograde cholangiopancreatography. Am J Med 1988; 84:590.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Pseudomonas aeruginosa infections associated with transrectal ultrasound-guided prostate biopsies--Georgia, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:776.</a></li><li><a class="nounderline abstract_t">Roberts R, Tarpay MM, Marks MI, Nitschke R. Erysipelaslike lesions and hyperesthesia as manifestations of Pseudomonas aeruginosa sepsis. JAMA 1982; 248:2156.</a></li><li><a class="nounderline abstract_t">FORKNER CE Jr, FREI E 3rd, EDGCOMB JH, UTZ JP. Pseudomonas septicemia; observations on twenty-three cases. Am J Med 1958; 25:877.</a></li><li><a class="nounderline abstract_t">Fabre V, Amoah J, Cosgrove SE, Tamma PD. Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough? Clin Infect Dis 2019; 69:2011.</a></li><li><a class="nounderline abstract_t">Bae M, Jeong Y, Bae S, et al. Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study. J Antimicrob Chemother 2021; 77:223.</a></li><li><a class="nounderline abstract_t">Bassetti M, Vena A, Giacobbe DR, Castaldo N. Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. Arch Med Res 2021; 52:817.</a></li><li><a class="nounderline abstract_t">Osmon S, Ward S, Fraser VJ, Kollef MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004; 125:607.</a></li><li><a class="nounderline abstract_t">Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745.</a></li><li><a class="nounderline abstract_t">Kim HS, Park BK, Kim SK, et al. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. BMC Infect Dis 2017; 17:500.</a></li><li><a class="nounderline abstract_t">Zhang Y, Chen XL, Huang AW, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect 2016; 5:e27.</a></li><li><a class="nounderline abstract_t">Bisbe J, Gatell JM, Puig J, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1988; 10:629.</a></li><li><a class="nounderline abstract_t">Baltch AL, Hammer M, Smith RP, Sutphen N. Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med 1979; 94:201.</a></li><li><a class="nounderline abstract_t">Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540.</a></li><li><a class="nounderline abstract_t">Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.</a></li><li><a class="nounderline abstract_t">Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.</a></li><li><a class="nounderline abstract_t">Peña C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56:1265.</a></li><li><a class="nounderline abstract_t">Herrera S, Bodro M, Soriano A. Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections. Curr Opin Infect Dis 2021; 34:686.</a></li><li><a class="nounderline abstract_t">Aliaga L, Mediavilla JD, Llosá J, et al. Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 2000; 19:871.</a></li><li><a class="nounderline abstract_t">Scheetz MH, Hoffman M, Bolon MK, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis 2009; 64:311.</a></li><li><a class="nounderline abstract_t">Jeddi R, Ghédira H, Ben Amor R, et al. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections. Hematology 2011; 16:160.</a></li><li><a class="nounderline abstract_t">Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.</a></li><li><a class="nounderline abstract_t">Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.</a></li><li><a class="nounderline abstract_t">Todeschini G, Franchini M, Tecchio C, et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998-1999; 3:99.</a></li><li><a class="nounderline abstract_t">Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701.</a></li><li><a class="nounderline abstract_t">Reyes MP, Palutke WA, Wylin RF. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972. Medicine (Baltimore) 1973; 52:173.</a></li><li><a class="nounderline abstract_t">Wieland M, Lederman MM, Kline-King C, et al. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. Medicine (Baltimore) 1986; 65:180.</a></li><li><a class="nounderline abstract_t">Reyes MP, Ali A, Mendes RE, Biedenbach DJ. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. Medicine (Baltimore) 2009; 88:294.</a></li><li><a class="nounderline abstract_t">Gouëllo JP, Asfar P, Brenet O, et al. Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. Crit Care Med 2000; 28:377.</a></li><li><a class="nounderline abstract_t">Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis 1990; 12:693.</a></li><li><a class="nounderline abstract_t">Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis 1983; 5:314.</a></li><li><a class="nounderline abstract_t">Dahl A, Hernandez-Meneses M, Perissinotti A, et al. Echocardiography and FDG-PET/CT scan in Gram-negative bacteremia and cardiovascular infections. Curr Opin Infect Dis 2021; 34:728.</a></li><li><a class="nounderline abstract_t">Maskarinec SA, Thaden JT, Cyr DD, et al. The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort. Open Forum Infect Dis 2017; 4:ofx132.</a></li><li><a class="nounderline abstract_t">Dawson NL, Brumble LM, Pritt BS, et al. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore) 2011; 90:250.</a></li><li><a class="nounderline abstract_t">Oechslin F, Piccardi P, Mancini S, et al. Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence. J Infect Dis 2017; 215:703.</a></li><li><a class="nounderline abstract_t">Chan BK, Turner PE, Kim S, et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018; 2018:60.</a></li><li><a class="nounderline abstract_t">Lin TI, Huang YF, Liu PY, et al. Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: Analysis of risk factors and treatment outcomes. J Microbiol Immunol Infect 2016; 49:516.</a></li></ol></div><div id="topicVersionRevision">Topic 2136 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691484" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence of Pseudomonas aeruginosa bacteremia: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902113" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9949667" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology and prognosis of Pseudomonas aeruginosa bacteremia in a tertiary care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306996" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695690" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30532566" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pseudomonas aeruginosa bacteremia among liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34215207" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19191643" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8086548" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pseudomonas aeruginosa bacteremia in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8021816" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serious Pseudomonas aeruginosa infection in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7638011" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pseudomonas aeruginosa infection in very low birth weight infants: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706821" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287873" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32015035" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2505076" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nitritoid reactions and angiotensin-converting-enzyme inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345116" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical Predictors of Pseudomonas aeruginosa Bacteremia in Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232033" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348267" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serious Pseudomonas infections associated with endoscopic retrograde cholangiopancreatography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855527" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pseudomonas aeruginosa infections associated with transrectal ultrasound-guided prostate biopsies--Georgia, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6811771" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Erysipelaslike lesions and hyperesthesia as manifestations of Pseudomonas aeruginosa sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13606140" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pseudomonas septicemia; observations on twenty-three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30882137" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34590681" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated Pseudomonas aeruginosa bloodstream infection: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34583850" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769745" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12955633" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716109" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27004762" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393785" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/110892" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377720" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155832" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34310454" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152313" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical significance of polymicrobial versus monomicrobial bacteremia involving Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19345039" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Morbidity associated with Pseudomonas aeruginosa bloodstream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21669056" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3927867" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pseudomonas bacteremia. Retrospective analysis of 410 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893372" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225988" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865983" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20407410" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084905" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19745688" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708170" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385771" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405476" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34751186" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Echocardiography and FDG-PET/CT scan in Gram-negative bacteremia and cardiovascular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28852678" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Risk of Cardiac Device-Related Infection in Bacteremic Patients Is Species Specific: Results of a 12-Year Prospective Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694647" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007922" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588855" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25442867" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pseudomonas aeruginosa infective endocarditis in patients who do not use intravenous drugs: Analysis of risk factors and treatment outcomes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
